Overview of receptor interactions of agonists and antagonists

Current Protocols in Pharmacology

Volumn , Issue SUPPL. 42, 2008, Pages

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Affinity; Drug classification; Efficacy; In vitro analysis; Receptor theory

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; PARTIAL AGONIST; RECEPTOR BLOCKING AGENT; RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ALKYLATION; ALLOSTERISM; CHEMICAL REACTION KINETICS; COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; MATHEMATICAL ANALYSIS; ORTHOSTERIC ANTAGONISM; PARTIAL AGONISM; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; REVIEW; THEORETICAL MODEL; TISSUE REACTION;

BINDING SITES; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG AGONISM; DRUG ANTAGONISM; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, DRUG; TISSUE CULTURE TECHNIQUES;

EID: 63849281595     PISSN: 19348282     EISSN: 19348290     Source Type: Journal    
DOI: 10.1002/0471141755.ph0401s42     Document Type: Review

References (26)

1. Arunlakshana, O. and Schild, H.O. 1959. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14:48-58.
2. Black, J.W. and Leff, P. 1983. Operational models of pharmacological agonist. Proc. R. Soc. London B Biol. Sci. 220:141-162.
3. Christopoulos, A. and Kenakin, T. 2002. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54:323-374.
4. Furchgott, R.F. 1966. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In Advances in Drug Research, Vol. 3 (N.J. Harper and A.B. Simmonds, eds.) pp. 21-55. Academic Press, San Diego.
5. Furchgott, R.F. 1972. The classification of adrenoceptors (adrenergic receptors): An evaluation from the standpoint of receptor theory. In Handbook of Experimental Pharmacology, Catecholamines, Vol. 33 (H. Blaschko and E. Muscholl, eds.) pp. 283-335. Springer-Verlag, New York and Heidelberg.
6. Gaddum, J.H. 1937. The quantitative effects of antagonistic drugs. J. Physiol. 89:7P-9P.
7. Gaddum, J.H., Hameed, K.A., Hathway, D.E., and Stephens, F.F. 1955. Quantitative studies of antagonists for 5-hydroxytryptamine. Q. J. Exp. Physiol. 40:49-74.
8. Jakubic, J., Bacakova, L., Lisa, V., El-Fakahany, E.E., and Tucek, S. 1997. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors Mol. Pharmacol. 52, pp. 172-179.
9. Kaumann, A.J. and Marano, M. 1982. On equilibrium dissociation constants for complexes of drug-receptor subtypes: Selective and nonselective interactions of partial agonistswith two plausible β-adrenoceptor subtypes mediating positive chronotropic effects of (β -isoprenaline in kitten atria. Naunyn-Schmiedebergs Arch. Pharmacol. 318:192-201.
10. Kenakin, T.P. 1980. Effects of equilibration time on the attainment of equilibrium between antagonists and drug receptors. Eur. J. Pharmacol. 66:295-306.
11. Kenakin, T.P. 1982. The Schild regression in the process of receptor classification. Can. J. Physiol. Pharmacol. 60:249-265.
12. Kenakin, T.P. 1985a. Prenalterol as a selective cardiostimulant: Differences between organ and receptor selectivity. J. Cardiovasc. Pharmacol. 7:208-210.
13. Kenakin, T.P. 1985b. Schild regressions as indicators of non equilibrium steady states and heterogeneous receptor populations. Trends Pharmacol. Sci. 6:68-71.
14. Kenakin, T.P. 1987. What can we learn from models of complex drug antagonism in classifying hormone receptors? In Receptor Biochemistry and Methodology, Vol. 6: Perspectives on Receptor Classification (J.W. Black, D.H. Jenkinson, andV.P. Gerskowitch, eds.) pp. 169-184. Alan R. Liss, New York.
15. Kenakin, T.P. 1992. Tissue response as a functional discriminator of receptor heterogeneity: The effects of mixed receptor populations on Schild regressions. Mol. Pharmacol. 41:699-707.
16. Kenakin, T.P. and Beek, D. 1987. The effects of Schild regressions of antagonist removal from the receptor compartment by a saturable process. Naunyn Schmiedebergs Arch. Pharmacol. 385:103-108.
17. Kenakin, T.P., Jenkinson, S., and Watson, C. 2006. Determining the potency and molecular mechanism of action of insurmountable antagonists. J. Pharmacol. Exp. Ther. 319;710-723.
18. Krebs, H.A. 1950. Body size and tissue respiration. Biochim. Biophys. Acta 4:249-269.
19. Krebs, H.A. and Henseleit, K. 1932. Untersuchungen über die Harnstoffbildung im Tierkorper. Z. Physiol. Chem. 210:33-66.
20. MacKay, D. 1966. A new method for the analysis of drug-receptor interactions. In Advances in Drug Research, Vol. 3 (N.J. Harper and A.B. Simmonds, eds.) pp. 1-19. Academic Press, San Diego.
21. MacKay, D. 1978. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J. Pharm. Pharmacol. 30:312-313.
22. Parascandola, J. 1986. The development of receptor theory. In Pharmacological Methods, Receptors and Chemotherapy, Vol. 3 (M.J. Parnham and J. Bruinvels, eds.) pp. 129-158. Elsevier/North-Holland, Amsterdam.
23. Paton,W. D. M. and Rang, H. P. 1965. The uptake of atropine and related drugs by intestinal smooth muscle of the guinea pig in relation to acetylcholine receptors. Proc. R. Soc. Lond. [Biol.] 163:1-44.
24. Schild, H.O. 1949. pAx and competitive drug antagonism. Br. J. Pharmacol. 4:277-280.
25. Stephenson, R.P. 1956. A modification of receptor theory. Br. J. Pharmacol. 11:379-393.
26. Tyrode, M.V. 1910. Mode of action of some purgative salts. Arch. Int. Pharmacodyn. Ther. 20:205-210.